|
Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome Clinical research trials and Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome. Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome clinical trial. Test subjects typically receive the most expert healthcare available for their Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome  Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome
Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome
For Condition: Retinitis Pigmentosa,Usher Syndrome
Status: Terminated
Sponsor(s): National Center for Research Resources (NCRR) , Oregon Health and Science University
Synopsis: OBJECTIVES: I. Examine the concentration of docosahexanoic acid (DHA) and other n-3 fatty acids in plasma, erythrocyte, and adipose tissue in patients with various forms of retinitis pigmentosa and Usher syndrome. II. Determine the synthesis and catabolism of DHA from linolenic acid in these patients. III. Determine the synthesis, absorption, and catabolism of DHA under different dietary conditions in these patients.
Details: PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study. Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects. Dietary histories are obtained from all patients and subjects. Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7, and then on days 10, 18, and 35. Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history at the end of each fatty acid supplementation period. All subjects must follow a diet free of seafood and fish oil supplements.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: - Retinitis pigmentosa, including: Usher syndrome (types I and II) Simplex - The following inheritance patterns eligible: X-linked recessive; Autosomal dominant; Autosomal recessive
Total Enrollment: 100
Location and Contact Information:
Overall Study Official:
WilliamConnor, Study Chair, Oregon Health and Science University
Oregon Health Sciences University
Portland, Oregon, 97201-3098
United States
Additional Information:
Study ID Numbers: 199/11904; OHSU-2650
Study Start Date: October 1999
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004345
Other Usher Syndrome Studies:
1. Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
2. Randomized Trial for Retinitis Pigmentosa
3. Effects of Lutein in retinitis pigmentosa
4. Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome
5. Study of Docosahexaenoic Acid (DHA) Supplementation in Patients with X-Linked Retinitis Pigmentosa
Related Studies:
Other Usher Syndrome Clinical Trials
Other Oregon Clinical Trials
Other Portland Clinical Trials
Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome
|
|
|
|
|
|
|
|
